# Impella Analyses Show Lower Mortality in High-Risk Heart Procedures

By John Kim

Canonical URL: https://www.tokenpost.com/news/business/45920
Published: 2026-11-01T15:23:03.000Z
Updated: 2026-11-01T15:23:03.000Z
Section: Business

> The analyses compared mortality among patients receiving the heart-pump support with rates reported in the recent CHIP-BCIS3 trial.

Johnson & Johnson said three clinical analyses found lower mortality rates among patients who received Impella support for high-risk coronary procedures than the rates reported in the recent CHIP-BCIS3 trial.